Inflammatory Bowel Disease and Colorectal Cancer

Author:

Fanizza Jacopo1,Bencardino Sarah1ORCID,Allocca Mariangela1,Furfaro Federica1,Zilli Alessandra1,Parigi Tommaso Lorenzo1,Fiorino Gionata2ORCID,Peyrin-Biroulet Laurent345678,Danese Silvio1ORCID,D’Amico Ferdinando1ORCID

Affiliation:

1. Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, 20132 Milan, Italy

2. IBD Unit, Department of Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, 00152 Rome, Italy

3. Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France

4. INSERM, NGERE, University of Lorraine, F-54000 Nancy, France

5. INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France

6. FHU-CURE, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France

7. Groupe Hospitalier Privè Ambroise Parè—Hartmann, Paris IBD Center, 92200 Neuilly sur Seine, France

8. Division of Gastroenterology and Hepatology, McGill University Health Center, Montreal, QC H4A 3J1, Canada

Abstract

Patients with inflammatory bowel diseases (IBDs), including both ulcerative colitis (UC) and Crohn’s disease (CD), are at a higher risk of developing colorectal cancer (CRC). However, advancements in endoscopic imaging techniques, integrated surveillance programs, and improved medical therapies have led to a decrease in the incidence of CRC among IBD patients. Currently, the management of patients with IBD who have a history of or ongoing active malignancy is an unmet need. This involves balancing the risk of cancer recurrence/progression with the potential exacerbation of IBD if the medications are discontinued. The objective of this review is to provide an updated summary of the epidemiology, causes, risk factors, and surveillance approaches for CRC in individuals with IBD, and to offer practical guidance on managing IBD patients with history of previous or active cancer.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3